Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases

Conclusions: Our study, along with similar reports in literature, highlights the need for close monitoring in patients who plan to switch from fingolimod to other treatments because of the risk of severe rebound. The etiopathogenic association between fingolimod and TDLs is not clear, but given the increasing reports of cases it should be taken into account for treatment selection in patients with this type of lesions.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research